Loading stock data…
AUTL
$1.71+0.11 (+6.88%)
Market ClosedLast close May 13
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Autolus Therapeutics plc in the Healthcare sector is trading at $1.71. Wall Street consensus targets $8.68 (9 analysts), implying a +407.5% move over the next 12 months. The stock is currently 37% below its 52-week high of $2.70, remaining 8.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +407.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$1.71
Potential Downside
0%
Whystock Fair Value$1.71
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$425.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-161.42%
Volume
Today's trading volume
1.97M
Recent News
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading
European equities traded in the US as American depositary receipts were little changed late Wednesda
European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading
European equities traded in the US as American depositary receipts opened the week on a flat note Mo
Autolus Therapeutics (AUTL) to Cut Workforce by 13% While Doubling 2026 Manufacturing Capacity
Autolus Therapeutics (NASDAQ:AUTL) is one of the best fast growing penny stocks to buy right now. On April 29, Autolus launched a strategic initiative to improve operational efficiency and accelerate its path to profitability for the acute lymphoblastic leukemia/ALL business. As part of this plan, the company will reduce its workforce by ~13%, a move […]
European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday Trading
European equities traded in the US as American depositary receipts were tracking lower late Thursday
3 Promising Penny Stocks With Market Caps Up To $900M
The market remained flat over the last week, yet it is up 28% over the past year with earnings expected to grow by 16% per annum in the coming years. In this context, identifying stocks that combine solid financials with growth potential is crucial for investors looking to capitalize on market opportunities. Penny stocks, often associated with smaller or newer companies, continue to be relevant as they can offer significant returns when backed by strong fundamentals.